Latest news with #NewHorizonMedicalSolutions
Miami Herald
02-07-2025
- Business
- Miami Herald
New Horizon Medical Solutions Adds AmchoPlast(TM) to its Industry-Best Product Portfolio
Next‑Gen Amnio-Chorionic Membrane for Enhanced Wound Care is Latest Offering in a Slew of New Products Focused on Increasing Patient Care LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / New Horizon Medical Solutions, a leader in advanced biologics and wound care innovation, today announced the launch and addition of AmchoPlast™ to its product portfolio. AmchoPlast is a premium amniotic‑chorionic membrane (amnion - chorion with intermediate layer) product designed to elevate outcomes across surgical and chronic wound indications. "AmchoPlast strengthens our pipeline of compliant, performance-driven biologics that align with modern wound care protocols," said Will Hall, CEO, New Horizon Medical Solutions. "This launch reflects our commitment to regenerative medicine, practice optimization, and elevating standards of care." Delivering superior benefits and practice optimization Engineered with amiotic-chorionic tissue, AmchoPlast serves as a natural biologic scaffold and barrier, supporting advanced wound care and non-immunogenic, the membrane is safe for a diverse patient population and a wide range of wound construction provides enhanced handling properties and slower degradation compared to single or bi-layer membranes Designed for clinical workflow and reimbursement ease Supplied in a sterile, ready-to-use format, AmchoPlast cuts procedural prep time and minimizes infection at room temperature, it supports versatile storage for hospitals, clinics, or mobile easy-to-handle, and available in multiple sizes, it facilitates precise application and reduces product wastage. "The addition of AmchoPlast cements our portfolio as the most complete in the biologics space," said D. Christopher Keil, SVP, strategy & corporate development. "We now offer providers and partners the broadest range of choices when selecting regenerative solutions from New Horizon." About AmchoPlast™ AmchoPlast, from Cellution Biologics, combines the power of amniotic and chorionic tissues with intermediate layer in a tri-layered construct. Intended to act as a barrier and provide protective coverage from the surrounding environment for acute and chronic wounds such as partial and full thickness wounds, pressure sores/ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (e.g., donor site/grafts, post-laser surgery, post-Mohs surgery, podiatric wounds, wound dehiscence), trauma wounds (e.g., abrasions, lacerations, partial thickness burns, skin tears), and draining wounds. For more information on the product, visit or contact New Horizon Medical Solutions directly at 702-960-2913. About New Horizon Medical Solutions New Horizon Medical Solutions is at the forefront of biologic innovation and practice optimization. The company develops regenerative tissue products supported by reimbursement expertise and operational efficiency, empowering providers to improve patient outcomes while maintaining compliance. --Media Contact Julian Rogers, Director of Corporate MarketingNew Horizon Medical SOURCE: New Horizon Medical Solutions
Miami Herald
26-06-2025
- Health
- Miami Herald
New Horizon Medical Solutions Expands Precise Bioscience Product Portfolio with Launch of AdvoGraft One and AdvoGraft Membrane Dual
Natural amniotic membrane-based wound care solutions with CMS-approved Q codes plus billing and reimbursement pathways for healthcare providers and payers available now. LAS VEGAS, NV / ACCESS Newswire / June 26, 2025 / New Horizon Medical Solutions, a leader in advanced biologics and wound care solutions, through its wholly-owned subsidiary, Precise Bioscience, LLC, announces the launch of AdvoGraft™ One and AdvoGraft Membrane Dual, two biologic wound care products that support natural healing by protecting both acute and chronic wounds. Both products use processed human placental tissue to better serve as a barrier between the wound and the surrounding environment during the healing process. Their availability is supported by newly approved CMS HCPCS Level II codes, Q4380 and Q4382, to simplify billing and reimbursement. "As a company, we're committed to advancing biologic wound care through clinically trusted, natural solutions and to growing the Precise Bioscience product group," said Will Hall, chief executive officer, New Horizon Medical Solutions. "The launch of AdvoGraft One and AdvoGraft Membrane Dual marks a significant milestone in that mission and in our mission as a company to offer the most comprehensive product portfolio for our providers and patients alike." AdvoGraft One (Q code Q4380): Key features and benefits Natural solutionSingle-layer amniotic membrane from human placental tissue, processed and sterilized for safe, biologically sourced wound supportedProvides a protective cover for various wound sizes and complianceCompliant with section 361 of the Public Health Service Act and 21 CFR part billingQ code Q4380 ("AdvoGraft One, per square centimeter") ensures easier reimbursement for clinicians and handlingSterile, room temperature-stored, and ready for physician in: 1x1, 2x2, 2x3, 2x4, 4x4, 4x6, 4x8 and 10x15cm sizes AdvoGraft Membrane Dual (Q code Q4382): Enhanced clinical benefits Dual-layer membraneCombines amniotic and chorionic membranes for greater structural wound protectionDesigned for wounds needing more robust coverage and productRegulated under section 361 of the PHS Act and 21 CFR part 1271 for consistency and reimbursementQ code Q4382 ("AdvoGraft Membrane Dual, per square centimeter") makes billing and claims easier for advanced wound useAvailable in multiple sizes, sterile, and ready to use, stored at room in: 1x1, 2x2, 2x3, 2x4, 4x4, 4x6, 4x8 and 10x15cm sizes A reliable, biologic wound care solution"The offering of the AdvoGraft family reflects our focus on furthering product development and championing long-term patient care," said D. Christopher Keil, SVP, strategy & corporate development, New Horizon Medical Solutions. "By adding additional CMS-approved Q codes, we're not only simplifying access to advanced wound care solutions for clinicians and patients but also ensuring practitioners have choices when making medically important decisions." For more informationHealthcare professionals and payers can learn more about AdvoGraft One and AdvoGraft Membrane Dual and the Precise Bioscience product line at or and by contacting New Horizon Medical Solutions at (702) 960-2913 or info@ About New Horizon Medical SolutionsNew Horizon Medical Solutions LLC focuses on biologically derived wound care products that meet high standards for safety and performance. Our commitment to natural, reliable solutions helps clinicians, payers, and patients redefine wound care with effective, trusted therapies. Precise Bioscience, LLC is a wholly owned subsidiary of New Horizon Medical Solutions providing the most advanced wound care solutions including Xcell Amnio Matrix™, Xcellerate® and more. Media contactJulian RogersDirector of Corporate SOURCE: New Horizon Medical Solutions
